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Abstract: Kaposi’s sarcoma is a vascular tumor of skin and viscera ﬁ  rst described in 1872. 
Prior to the 1980s, this disease was rarely seen in the Western world, but was quite prevalent in 
Sub-Saharan African countries. Since the onset of the HIV pandemic in the 1980s, the incidence 
of Kaposi’s sarcoma has increased markedly in Africa and continues to be a signiﬁ  cant problem 
in association with AIDS in Western countries. Many therapies have been demonstrated to be 
effective in the treatment of HIV-related Kaposi’s sarcoma, including alitretinoin gel, interferon 
alpha, and various forms of cytotoxic chemotherapy. Antiretroviral therapy combined with 
cytotoxic agents has yielded signiﬁ  cantly greater efﬁ  cacy than chemotherapy alone. However, 
as reviewed in this report, pegylated liposomal doxorubicin has been established as the treatment 
of choice for patients with AIDS-associated Kaposi’s sarcoma in Western countries. Compelling 
preclinical and clinical evidence, reviewed herein, has demonstrated that the nanoparticle 
(pegylated liposome) delivery system of this formulation leads to greater tumor localization of 
doxorubicin and consequent improved efﬁ  cacy, as well as reduced toxicity.
Keywords: liposomal doxorubicin, pegylated liposomal doxorubicin, Kaposi’s sarcoma, 
liposomal daunorubicin, liposomal anthracyclinces
Introduction
Kaposi’s sarcoma (KS) is the most common malignancy seen in patients with human 
immunodeﬁ  ciency virus infection, occasionally as the initial manifestation acquired 
immunodeﬁ  ciency syndrome (AIDS) (Wang et al 1995). Prior to the AIDS epidemic, 
KS was uncommon, occurring primarily in men in Africa, the Mediterranean area, or 
Eastern Europe (Mitsuyasu 2000). Although it was an exceedingly common complication 
of AIDS in western countries in the 1980s at the onset of the epidemic, in the 1990s the 
incidence of AIDS-related KS (AIDS-KS) in developed countries decreased dramatically; 
between 1990 and 1997, that decline was 10% per year. An additional decline in the 
incidence of AIDS-KS occurred in association with widespread implementation of highly 
active antiretroviral therapy (HAART) in the late 1990s. Also, it has been speculated that 
safer sexual practices among homosexual men may have led to reduced transmission 
of human herpesvirus-8 (HHV-8), the virus associated with all forms of KS, and that 
the introduction of more effective antiretroviral treatments with associated reduction 
in immunodeﬁ  ciency may also have resulted in a more effective immune response to 
HHV-8. Any or all of these factors could account for the observed decline in incidence 
of AIDS-KS over the course of the epidemic.
Nevertheless, AIDS-KS continues to be diagnosed among HIV-infected persons. Control 
of HIV infection is not uniformly achieved with HAART, either because of drug resistance 
and/or as a result of poor adherence to prescribed drug regimens. Additionally, some patients 
continue to develop AIDS-KS despite effective HIV suppression. Furthermore, rates of 
AIDS-KS continue to rise in parts of Africa where rates of both HIV and HHV-8 infection 
are high and HIV treatment is not widely available.International Journal of Nanomedicine 2007:2(3) 346
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Clinical presentation of AID-KS
AIDS-KS is a multifocal, systemic disease that usually ﬁ  rst 
appears as pink, red, purple, or brownish-black nodules, 
macules, patches, or plaques on the skin or, less often, on the 
oral mucosa (Wang et al 1995). In the setting of HIV infection, 
AIDS-KS lesions often occur on the upper body, especially 
the head and neck. Disease conﬁ  ned to the lower extremities 
is more common in non-HIV-associated KS (Misuyasu 2000). 
Oral lesions have reportedly accounted for 22% of the sites 
of initial presentation in AIDS-KS. Lesions of AIDS-KS 
may develop in the lungs, gastrointestinal tract, and lymph 
nodes and have also been described in the gallbladder, on 
the mucosa of the vocal cords and conjunctiva, genitalia, 
liver, spleen, heart, bone, thyroid gland, and/or bone marrow 
(Wang et al 1995). Depending on their location and size, 
AIDS-KS lesions may be disﬁ  guring and can cause edema, 
pain, gastrointestinal bleeding, and tooth loss, and can lead 
to nutritional deﬁ  ciencies and disﬁ  gurement with consequent 
social isolation. Moreover, lesions in critical sites can interfere 
with eating, speaking, breathing, and sometimes produce 
fatal consequences (Peters et al 1991; Wang et al 1995). The 
course of the disease varies from development of single or 
a few indolent lesions with minimal progression over time, 
to aggressive, debilitating, widespread disease with severe 
complications emerging within a short time (Wang et al 
1995; Krown 2004).
Rationale for use of liposomal 
anthracyclines in treatment of 
AIDS-KS
Several liposomal anthracycline products have been 
investigated for the treatment of AIDS-KS. In particular, a 
polyethylene glycol-coated (“pegylated”) liposomal product 
with trade names Doxil® or Caelyx® (doxorubicin HCl 
liposome injection [PLD]; the former distributed in the US 
by Tibotec Therapeutics, Division of Ortho Biotech Products, 
LP, Bridgewater, NJ; the latter distributed outside the US 
by Schering-Plough Corp.), received accelerated approval 
from the United States Food and Drug Administration (US 
FDA) in November 1995 for treatment of patients with 
AIDS-KS whose disease either had progressed on prior 
combination chemotherapy or who were intolerant of such 
therapy (Doxil 2001). In April 1996, the non-pegylated 
liposomal product, DaunoXome® (DNX, daunorubicin citrate 
liposome; Gilead Sciences, Foster City, CA) was approved 
as treatment of AIDS-KS for which no prior chemotherapy 
had been administered (“ﬁ  rst-line” treatment) (DaunoXome 
1996). Results of a phase II trial in AIDS-KS patients were 
also reported for a non-pegylated formulation of liposomal 
doxorubicin, Myocet® (liposome-encapsulated doxorubicin 
citrate complex; Medeus Pharma, Stevenage, Herts UK) 
(Cheung et al 1999), but this agent is not approved for 
treatment of AIDS-KS in the US.
Encapsulation of conventional doxorubicin within 
liposomes was expected to preferentially distribute drug into 
tumors with “leaky” blood vessels, a condition which it was 
believed would facilitate the extravasation of liposomes into 
tumor stroma (Allen and Martin 2004). Because AIDS-KS 
lesions contain dilated vascular spaces ﬁ  lled with extravasated 
erythrocytes, good drug uptake due to similar extravasation 
of liposomes was anticipated. “Pegylation” of liposomes was 
expected to offer advantage over conventional liposomes 
by preventing early clearance of circulating liposomes by 
macrophages of the reticuloendothelial system. This would 
theoretically lead to longer circulation time for the liposomes 
and thereby enhance their opportunity to traverse tumor 
vasculature where extravasation could occur.
In vitro studies demonstrated the antitumor activity of 
conventional doxorubicin in KS-derived cell cultures (Logan 
et al 1991). Other in vitro studies showed that exposure to 
PLD inhibited the proliferation of KS-derived cells to a greater 
extent than the proliferation of endothelial cells, monocytes, 
and smooth muscle cells (Sturzl et al 1994). It was also shown 
that PLD increased the expression of monocyte chemoattractant 
protein-1 in KS cells, a substance believed to lead to increased 
migration of monocytes into the tumor (Sturzl et al 1994). Before 
initiation of clinical studies, it was shown in animal models of  KS 
that PLD was preferentially taken up into tumor tissue (Huang 
et al 1993). Using a model of KS dermal lesions in transgenic 
mice bearing the HIV tat gene (Vogel et al 1998; Huang et al 
1993), pegylated liposomes were shown to extravasate into the 
interstitial spaces between spindle-shaped KS cells. Liposomes 
were found predominantly within the lesion in the region adjacent 
to the epidermis, with dense concentrations around abnormal 
blood vessels. In addition, electron microscopy showed that some 
macrophages and spindle cells had ingested intact liposomes. 
Skin biopsies of patients under treatment with PLD provided 
additional evidence for the preferential tumor uptake observed 
in animal models (Vail et al 2004). When encapsulated in a 
pegylated liposome, doxorubicin concentrations in KS lesions 
reached 10–20 times those in normal skin (Northfelt et al 
1995). In addition, it was shown that more doxorubicin was 
delivered to AIDS-KS lesions when administered as PLD than 
as conventional doxorubicin. Kaposi’s lesions from 18 patients 
were biopsied 72 hours after intravenous injection of either PLD International Journal of Nanomedicine 2007:2(3) 347
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or conventional doxorubicin (Northfelt et al 1996). Regardless of 
the dose, tissue levels of doxorubicin were approximately 5–11 
times higher in the AIDS-KS lesions of patients treated with PLD 
compared with AIDS-KS lesions in patients given comparable 
doses of conventional doxorubicin.
Efﬁ  cacy of liposomal anthracyclines 
in clinical trials of treatment for 
AIDS-KS
Results of phase I/II trials of PLD in relatively unselected 
cohorts of patients with AIDS-KS demonstrated overall 
response rates (complete and partial response [CR + PR]) 
ranging from 38% to 100% (Sturzl et al 1994; Hengge 
et al 1993, 2001; Simpson et al 1993; Bogner et al 1994; 
James et al 1994; Wagner et al 1994; Bergin et al 1995; 
Harrison et al 1995; Goebel et al 1996; Northfelt et al 
1997; Grunaug et al 1998; Newell et al 1998; Nuncez et al 
2001). To illustrate these ﬁ  ndings we will focus on the 
trial reported by Northfelt et al (1997) (Table 1), which 
provided the data that led to initial approval of PLD by the 
United States Food and Drug Administration (US FDA). 
It was limited to patients who had experienced disease 
progression or intolerable toxicities during treatment with 
the combination of doxorubicin, bleomycin, and vincristine 
(ABV) or the combination of bleomycin and vincristine 
(BV) chemotherapy. The 53 patients enrolled in this 
trial received 20 mg/m2 of PLD intravenously once every 
3 weeks; 19 patients (36%) achieved PRs and one achieved 
a complete clinical response. Among those who had previ-
ously experienced disease progression when receiving a 
conventional doxorubicin-containing regimen (eg, ABV 
rather than BV), the PR rate was 32%. Median duration of 
response and time to treatment failure in all patients was 
128 and 134 days, respectively. Of the 53 patients, 48 had 
raised indicator lesions at baseline; a complete ﬂ  attening 
of these lesions occurred in 48% of these patients and 68% 
achieved partial or complete responses. Forty-eight of the 
patients had red or purple indicator lesions at baseline; in 
56% of these patients the lesions changed to a less notice-
able color, and 82% of these patients achieved partial or 
complete responses. Among the 23 patients with edema 
at study entry, study therapy reduced edema in 83%, and 
100% of those achieved PR or CR. Of the 22 patients with 
pain at baseline, 45% (70% of whom attained PR or CR) 
had pain reduction. These apparent beneﬁ  ts of PLD did 
not result in PR or CR in some patients because they failed 
to fulﬁ  ll some other qualiﬁ  cation for response, such as no 
progression at other sites.
Although not addressed speciﬁ  cally in the study described 
above, other observations demonstrated that PLD could 
be effective in relieving symptoms and possibly prolong-
ing survival of patients with pulmonary AIDS-KS. In a 
retrospective analysis of 20 patients, including nine who had 
received prior chemotherapy, 11 of 16 patients whose tumors 
could be evaluated had improved ﬁ  ndings on chest radiog-
raphy, and the average arterial partial pressure of oxygen 
(pO2) for all patients rose to 76 from 55.5 mmHg (p < 0.01). 
Dyspnea and/or cough resolved in 12 of 16 patients who had 
been symptomatic before treatment (Grunaug et al 1998).
The evidence supporting the use of PLD alone as ﬁ  rst-line 
therapy is derived from two randomized trials in which patients 
on the control arm received either ABV or BV (Table 2) 
(Stewart et al 1998; Northfelt et al 1998). In the trial conducted 
by Stewart et al (1998) 241 patients who had received no prior 
cytotoxic chemotherapy were randomized to receive either 
PLD 20 mg/m2 or BV (bleomycin 15 mg/m2 and vincristine 1.4 
mg/m2). Both regimens were administered intravenously every 
3 weeks for six cycles. Overall best response (CR plus PR) was 
signiﬁ  cantly higher with PLD (58.7% vs 23.3%; p  <  0.001), as 
was end-of-treatment response (38.8% vs 14.2%; p < 0.001). 
The end-of-treatment response reﬂ  ected the patient’s status at the 
time further therapy was discontinued; the response designation 
was scored within 21 days of the last dose of therapy and must 
have been sustained for at least 4 weeks. The average time to 
response was 49 days with PLD vs 57 days with BV. The mean 
duration of response was similar for the groups (160 days with 
PLD vs 157 days with BV). PLD produced signiﬁ  cantly greater 
improvements in lesion thickness, nodularity, edema, color, 
Table 1 Efﬁ  cacy of pegylated-liposomal doxorubicin in the 
treatment of AIDS-related Kaposi’s sarcoma after failure of 
standard chemotherapy (Northfelt et al 1997)
Best response  All patients   Doxorubicin
 (n  =  53)  failurea
   (n  =  28)
Complete clinical  1 (2%)  0
Partial  19 (36%)  9 (32%)
Stable  19 (36%)  14 (50%)
Progression  14 (26%)  5 (18%)
Median time 
  (days) to PR   109  109
Median duration
  (days) of PR   128  127
Median time (days) to
treatment Failure  134  148
aPatients whose AIDS-KS progressed on a combination regimen containing 
doxorubicin.International Journal of Nanomedicine 2007:2(3) 348
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pain, and size than did BV. Among those treated with PLD, the 
incidence of pulmonary symptoms (dyspnea, cough, chest pain, 
or effusion) dropped from 23.1% to 10.6% (p = 0.002), while 
for those on the BV regimen, pulmonary symptoms decreased 
from 24.4% to 20.2% (p = 0.25). The incidence of gastrointestinal 
symptoms related to AIDS-KS (bleeding, early satiety, or 
dysphagia) decreased from 16.3% at baseline to 3.8% with PLD 
treatment (p < 0.001), and from 17% to 9.4% (p = 0.06) with 
BV treatment. Mortality was similar in the two groups: 15.7% 
with PLD vs 14.2% with BV, with a mean time to death of 239 
days versus 160 days, respectively. Only three of the deaths were 
caused by KS and none was attributed to the treatments studied. 
This study, as well as most of the others trials described here, was 
conducted before the introduction of HAART. Because survival 
of AIDS-KS patients is determined primarily by opportunistic 
infections and other non-KS complications of AIDS, the 
durations of survival in these studies is shorter than might be 
expected today with availability of more effective treatment of 
the underlying disease.
In the second randomized trial of ﬁ  rst-line therapy with 
PLD for AIDS-KS (Northfelt et al 1998), also performed 
before the introduction of HAART, 258 patients with no 
prior chemotherapy were randomized to receive either PLD 
(20 mg/m2) or ABV (conventional doxorubicin 20 mg/m2, 
bleomycin 10 mg/m2, and vincristine 1 mg), administered 
every 2 weeks. The overall response was signiﬁ  cantly better 
with PLD than with ABV (45.9% vs 24.8%; p < 0.001) (Table 2). 
The time to response was again shorter with PLD (median, 
39 days vs 50 days with ABV; p = 0.014). Compared with 
PLD, more than three times as many patients discontinued 
ABV because of an adverse event (37% vs 11%). PLD-treated 
patients remained on treatment longer either because it was 
well tolerated or because they responded to treatment. More 
rapid dropout of patients in the ABV treatment group might 
have inﬂ  uenced cumulative response rates, but the study 
did not examine this possibility. Signiﬁ  cant differences 
between the treatments favored PLD in the frequency 
with which lesions decreased in size, indicator lesions 
ﬂ  attened, lesion color returned closer to that of normal skin, 
pulmonary dysfunction improved, pain decreased, head 
and limb mobility improved, exercise tolerance increased, 
sleep disturbances decreased, and a sense of social well-
being increased. The treatments showed no significant 
differences in reduction of lesion edema or pain, or patients’ 
ability to walk or wear clothing more easily. Neither the 
median duration of response (PLD, 90 days; ABV, 92 days; 
p = 0.234) nor the median overall survival (both groups, 160 
days differed between treatment groups.
Patients enrolled in the trial comparing PLD with ABV 
(Northfelt et al 1998) were asked to complete a 30-item 
AIDS-related health-related quality of life questionnaire 
before treatment (baseline), every 2 weeks during treatment, 
and approximately 21 days post-treatment (Osoba et al 2002). 
Twenty-two items were assessed within 9 domains: general 
health, pain, social functioning, and overall quality of life (1 item 
each); mental health (5 items); energy/fatigue (4 items); health 
distress (4 items); and cognitive functioning (4 items). Scores at 
baseline and end of treatment were transformed to a scale from 
0 to 100, with higher scores indicating better health.
In each of the domains there was an improvement in 
health-related quality of life associated with PLD treatment, 
and six of these nine changes were statistically signiﬁ  cant 
(Table 3) (Osoba et al 2001). In contrast, ABV treatment 
resulted in improved health-related quality of life in only 
two domains and in worsened health-related quality of life 
in three domains, two of which were signiﬁ  cantly reduced. 
Table 2 Response rates in randomized trials comparing a liposomal anthracycline with ABV or BV  a,  b
   Stewart et al 1998    Northfelt et al 1998
  PLD (Doxil)   BV  P value  PLD (Doxil)   ABV  P value
  (n = 121)  (n = 120)    (n = 133)  (n = 125) 
CR, %  6  1  <0.001  1  0  NS
PR, %  53  22  <0.001  45  25  <0.001
CR + PR, % (95% CI)  59 (50–67)  23 (16–31)    46 (37–54)  25 (17–32) 
Stable disease, %  38  68    53  67 
Progressive disease, %  0  4    2  8 
Not assessable, %  3  5    0  0 
aBest response during treatment.
bPartial response deﬁ  ned as absence of new cutaneous or oral lesions, new visceral sites of involvement, or the appearance or worsening or tumor-associated edema or 
effusions plus at least one of the following: a 50% decrease in the sum of the products of the skin lesions, complete ﬂ  attening of greater than 50% of all previously raised 
skin lesions, a 50% decrease in the sum of the products of the largest perpendicular diameters of prospectively selected indicator skin lesions, or the patient met the crite-
ria for Complete Clinical Response, except that residual tumor-associated edema or effusion was present. The response was required to persist for at least 4 weeks.
Abbreviations: ABV, doxorubicin, bleomycin, vincristine; BV, bleomycin, vincristine; CR, complete response; PR, partial response; NS, not signiﬁ  cant.International Journal of Nanomedicine 2007:2(3) 349
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There was a signiﬁ  cant difference between the two treatments 
in four domains: general health, social functioning, and 
energy/fatigue. A clinically signiﬁ  cant improvement was 
deﬁ  ned as a change of 10 points or more from baseline in 
the overall quality-of-life score, and more patients in the 
PLD group than the ABV group achieved this endpoint (65% 
vs 43%, p = 0.0008). The duration of clinically signiﬁ  cant 
improvement in overall quality of life was also longer in the 
PLD-treated group than in the ABV group (p = 0.049).
To determine whether the addition of other agents to PLD 
might lead to improved treatment outcome, the AIDS Clinical 
Trials Group performed a study which randomized patients 
who had not received prior chemotherapy to receive treatment 
with PLD (20 mg/m2) either alone or in combination with 
BV (bleomycin 10 U/m2, and vincristine 1 mg), administered 
every 2 weeks (Misuyasu et al 1997). Among 126 evaluable 
patients, overall responses were similar in the two groups: 
79% with PLD alone versus 80% when combined with BV. 
Five patients in each group experienced a CR. Median time 
to tumor progression or death was also similar: 29 and 32 
weeks, respectively. Patients treated with PLD alone showed 
a trend toward better survival at the time of an interim analy-
sis; with the single-agent, quality of life decreased less rapidly 
during treatment. The authors concluded that adding BV to 
PLD offered no additional beneﬁ  t.
Safety of pegylated liposomal 
doxorubicin in clinical trials
Toxicities observed in phase I/II studies of PLD for KS are 
shown in Table 4 (Hengge et al 1993; Bogner et al 1994; 
Harrison et al 1995; Goebel et al 1996; Northfelt et al 
1997; Grunaug et al 1998; Newell et al 1998). Neutropenia 
was progressive with succeeding courses of PLD and 
was the most common dose-limiting side effect, with an 
incidence that ranged from 28.6% to 85% in various tri-
als. This wide variation was likely related to the degree to 
which AIDS had compromised the marrow in addition to 
the effects of prior chemotherapy. In these trials, the over-
all incidences of alopecia and nausea and vomiting were 
low (generally <20%). In contrast to studies of patients 
with solid tumors in which PLD was administered at a 
higher dose, the incidences of hand-foot syndrome (HFS; 
0%–2%) and infusion reactions (0%–15%) were relatively 
low. Infusion reactions to PLD were characterized by some 
or all of the following: ﬂ  ushing, tachycardia, dyspnea, 
hypertension or hypotension, chest pain, abdominal pain, 
and back pain.
Table 3 Changes in health-related quality-of-life parameters in patients with Kaposi’s sarcoma
  PLD (Doxil) (n = 118)    ABV (n = 114)
Domain  No. of  Change  P  No. of   Change  P  P value
 patients  from  valueb patients from  valueb between
   baselinea     baselinea   groupsc
General health  91  3.3  NS  85  –3.3  0.05  0.02
Pain 73  8.3  0.01  74  0  NS  0.01
Cognitive functioning  70  5.0  0.008  61  0  NS  NS
Mental health  93  3.3  0.03  89  0  NS  NS
Overall quality of life  90  4.0  0.05  85  –2.0  NS  NS
Social functioning  76  10.0  0.004  69  0  NS  0.03
Energy/fatigue 93 3.3  NS  88 –5.0  0.004  0.002
Health distress  91  8.3  <0.001  88  1.4  NS  NS
Health transition  76  4.0  NS  78  1.4  NS  NS
aScores at baseline and end of treatment ranged from 0 to 100, with higher scores and positive changes Indicating better health.
bWilcoxon signed-rank test comparing the change from baseline to the end of the treatment within treatments.
cWilcoxon rank-sum test comparing the change from baseline to end of treatment between treatments.
Abbreviations: ABV, doxorubicin, bleomycin, vincristine; NS, not signiﬁ  cant.
Table 4 Efﬁ  cacy of pegylated-liposomal doxorubicin in the treat-
ment of AIDS-related Kaposi’s sarcoma after failure of standard 
chemotherapy: adverse events (Northfelt et al 1997)
Event   All eventsa  Severe
(n = 53)   (% patients)   (% patients)
Any adverse event  76%  30%
Leukopenia 40%  17%
Nausea and/or vomiting  19%  0%
Alopecia 9%  0%
Asthenia 9%  2%
Fever 8%  2%
Diarrhea 6%  2%
Thrombocytopenia 6%  2%
aAdverse events occurring in ≥5% of patients, thought to be possibly or probably 
related to pegylated-liposomal doxorubicin.International Journal of Nanomedicine 2007:2(3) 350
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A similar safety proﬁ  le was observed in the phase III 
randomized comparisons of PLD and either BV or ABV 
(Stewart et al 1998; Northfelt et al 1998). Compared with these 
combination regimens, PLD was associated with a reduced 
incidence of nausea/vomiting, alopecia, and neuropathy (from 
vincristine, which is used in both the BV and ABV regimens) 
(Table 5). In the trial of PLD vs ABV (Northfelt et al 1998) 
myelosuppression and fever were less severe with PLD, but 
this did not translate into a reduced incidence of infection. In 
the comparison with BV (Stewart et al 1998), PLD was more 
myelosuppressive because neither bleomycin nor vincristine 
is associated with substantial bone marrow toxicity. HFS was 
uncommon with the PLD doses and schedules used in these 
trials. No cases occurred in either group of one trial (Stewart 
et al 1998), and in the other trial, 4% of PLD-treated patients 
and 1% of ABV-treated patients experienced HFS (Table 5). 
Mucositis, stomatitis, and infusion reactions such as dyspnea 
and hypotension occurred more frequently on the PLD arms; 
infusion reactions that occurred with BV consisted primarily 
of fever and rigors.
Comparative trial: PLD vs DNX
PLD was initially granted “accelerated approval” by the US 
FDA, when the only data available for regulatory review were 
from uncontrolled trials in patients with AIDS-KS which 
was refractory to conventional therapy, or in patients who 
were intolerant of conventional chemotherapy regimens. At 
the request of the US FDA, a double-blind randomized trial 
of PLD and DNX treatment for AIDS-KS was undertaken 
primarily to conﬁ  rm earlier data for PLD, rather than as a 
comparison between the two drugs (Henry et al 2002). In this 
trial patients were randomized in a 3:1 ratio to receive PLD 
or DNX, respectively. The nature of the trial and the small 
number of patients enrolled precluded a robust statistical 
analysis, and p values were not calculated.
For enrollment patients were required to have at least 
one KS-related symptom at baseline so that clinical beneﬁ  t 
could be assessed. Patients were initially eligible only if they 
were refractory to conventional chemotherapy, but the trial 
was ultimately amended to allow patients without or with 
limited prior chemotherapy because of slow accrual to the 
study. As a result, 7 of 80 patients enrolled had received prior 
chemotherapy. Patients were randomized to PLD 20 mg/m2 
or DNX 40 mg/m2 given intravenously every 2 weeks for 
up to six cycles.
Although statistical tests were not performed, differences 
in clinical beneﬁ  t and tumor response tended to favor PLD 
(n = 60) over DNX (n = 19) among the patients who received 
at least one dose of study treatment (Table 6). Clinical beneﬁ  t 
was deﬁ  ned as improvement from baseline in at least one 
Table 5 Incidences (%) of adverse events in randomized trials comparing a liposomal anthracycline with ABV or BV
  Stewart et al 1998      Northfelt et al 1998
  PLD (Doxil)  BV  P value  PLD (Doxil)  ABV  P value
  (n = 121)  (n = 120)    (n = 133)  (n = 125) 
Neutropenia grade 3/4  72  51  <0.001  36  42 
Neutropenia grade 3  29  13
Neutropenia grade 4        6  14 
G-CSF required        44  53 
Fever 16  25  0.08  0  4 
Sepsis  7 2    6 2 
OIs 50  30  <0.002  37  30 
Oral candidiasis  31  17  0.02     
Anemia  18 15    10 11 
Thrombocytopenia 15  12   3  6 
Alopecia  3 8    1 19  <0.001
Neuropathy – all grades  3  14  <0.005  6  14  0.002
Constipation 2  11  <0.01    
Nausea (all grades)  12  17       
Nausea/vomiting grade 3/4  16  25    15  34  <0.001
Stomatitis grade 3/4   7  5    5  2  0.026
Infusion  reactions  4 6    5 0 
Skin rash   12  9       
Hand-foot syndromea       4  1 
aIncludes 2 skin rashes in PLD treated patients not called hand-foot syndrome but totally consistent with the syndrome. 
Notes: Unless noted, differences are not statistically signiﬁ  cant.
Abbreviations: ABV, doxorubicin, bleomycin, vincristine; BV, bleomycin, vincristine; G-CSF, granulocyte colony-stimulating factor; OI, opportunistic infection.International Journal of Nanomedicine 2007:2(3) 351
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AIDS-KS symptom category that lasted for 28 days or longer 
in the absence of disease progression or severe drug-induced 
toxicity. Using this deﬁ  nition, 80% of PLD-treated patients 
and 63% of DNX-treated patients experienced clinical beneﬁ  t. 
The deﬁ  nition of sustained clinical beneﬁ  t was more restrictive, 
and involved improvement in at least one symptom category 
for 28 days or longer with no worsening of other symptom 
categories and no increase in medical interventions either 
before or during that period. Sustained clinical beneﬁ  t was 
observed in 37% of PLD-treated patients and 16% of DNX-
treated patients. An external HIV/AIDS expert who was 
blinded to treatment allocation determined that clinical study 
photographs showed clinical efﬁ  cacy rates of 35% for PLD 
and 38% for DNX.
Partial tumor response was deﬁ  ned as one or more of the 
following: (1) no new lesions (skin or oral), no new visceral 
sites of involvement, no appearance or worsening of tumor-
associated edema or effusions, and a 50% or greater decrease 
in the number of all previously existing lesions lasting for 
at least 4 weeks; (2) complete ﬂ  attening of at least 50% of 
all previously raised lesions; (3) a 50% decrease in the sum 
of the products of the largest perpendicular diameters of 
the indicator lesions; or (4) the patient met the criteria for 
complete clinical response except residual tumor-associated 
edema or effusion. Using these criteria, 55% of patients in 
the PLD group and 32% of patients in the DNX group had a 
PR to liposomal anthracycline therapy. There was a positive 
correlation between clinical beneﬁ  t and tumor response 
(Pearson correlation coefﬁ  cient, 0.25; p = 0.028). Ninety-two 
percent of patients who responded to PLD experienced clinical 
beneﬁ  t, and 42% of responders in the PLD group experienced 
sustained clinical beneﬁ  t.
There were concerns that the introduction of HAART, which 
occurred around the time the study began to enroll patients, might 
have confounded the results of the study. An additional analysis 
of the data thus considered antiretroviral therapy to be a potential 
confounding factor if it was begun within 28 days of study entry 
or was changed during the study. The observed rates of clinical 
beneﬁ  t were not signiﬁ  cantly different between patients who met 
these criteria for potentially confounding treatment and those who 
did not (26% and 35%, respectively; p = 0.461).
Differences in the nature and frequency of side effects from 
the two drugs were smaller than might have been expected from 
indirect comparisons drawn from data shown in Tables 6 and 7. 
HFS and infusion reactions were seen only with PLD. In all but 
one of the patients who experienced HFS or infusion reactions, 
the reactions were grade 1/2, and none of the reactions caused 
patients to discontinue treatment.
Conclusion
Many new and interesting agents are under development for 
treating AIDS-KS, including angiogenesis inhibitors, locally 
applied and oral retinoids, more effective anti-retroviral 
agents, and drugs targeting HHV-8. However, liposomal 
anthracyclines are still considered by many to be the initial 
drugs of choice for this disease when it is advanced and 
symptomatic.
Phase 1 clinical trials conﬁ  rmed that delivery via pegylated 
liposomes does concentrate doxorubicin in AIDS-KS lesions 
more effectively that does treatment with conventional 
doxorubicin, as well as concentrating doxorubicin to a 
greater degree in AIDS-KS lesions than in adjacent normal 
skin (Northfelt et al 1993, 1995). A number of phase II 
clinical trials demonstrated substantial effectiveness and 
good tolerability of PLD in treatment of AIDS-KS, even in 
patients who had previously been treated with conventional 
chemotherapy, including conventional doxorubicin (Sturzl 
et al 1994; Hengge et al 1993, 2001; Simpson et al 1993; 
Bogner et al 1994; James et al 1994; Wagner et al 1994; 
Bergin et al 1995; Harrison et al 1995; Goebel et al 1996; 
Northfelt et al 1997; Grunaug et al 1998; Newell et al 1998; 
Nuncez et al 2001).
Finally, in phase III clinical trials in which PLD com-
pared with conventional treatment with BV or ABV, PLD 
was associated with a higher response rate, shorter time to 
response, and less toxicity in patients with AIDS-KS (Stewart 
et al 1998; Northfelt et al 1998). PLD also improved several 
domains of health-related quality of life compared with ABV 
(Osoba et al 2001). Thus, liposomal anthracyclines, and 
in particular PLD, appear to offer comparable or superior 
efﬁ  cacy, improved tolerability, and improved quality of 
life relative to conventional chemotherapy for AIDS-KS, 
validating the theoretical advantage of pegylated liposomal 
drug delivery in this disease.
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